Article

Optimizing transcriptome-based synthetic lethality predictions to improve targeted therapy / immunotherapy treatment prioritization in non-metastatic breast cancer: BC-SELECT

2024-08-21

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Patients with non-metastatic triple-negative (TNBC) or HER2-positive (HER2+) breast cancer do not have tools to predict treatment response or prioritize options prior to starting therapy. Pathologic complete response (pCR) is a proxy that requires neoadjuvant treatment. BC-SELECT leverages genetic interactions (e.g. synthetic lethality (SL)/rescue (SR)) to predict treatment...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b11db2be-cef0-5d9f-9533-b3e3de80d4f7
DOI: 10.1101/2024.08.15.608073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimizing transcriptome-based synthetic lethality predictions to improve targeted therapy / immunotherapy treatment prioritization in non-metastatic breast cancer: BC-SELECTDOI 10.1101/2024.08.15.608073Read

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeSemantic proximity Read

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast CancerSemantic proximity Read

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseSemantic proximity Read

Retrospective multi-cohort validation of a real-world transcriptomics-guided machine learning model for treatment response prediction in breast cancerSemantic proximity Read

A machine learning framework for supervised treatment response prediction from tumor transcriptomics: A large-scale pan-cancer studySemantic proximity Read

Molecular determinants of drug response in TNBC cell lines.Semantic proximity Read

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read

Relationship Between Gene Expression and Drug Response in Triple-Negative Breast Cancer: Leveraging Single-Cell RNA Sequencing and Machine Learning to Identify Biomarker ProfilesSemantic proximity Read

Personalized tumor combination therapy optimization using the single-cell transcriptomeSemantic proximity Read

Predicting patient treatment response and resistance via single-cell transcriptomics of their tumorsSemantic proximity Read

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancerSemantic proximity Read

Predicting drug response from single-cell expression profiles of tumoursSemantic proximity Read